Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade.


Journal

Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780

Informations de publication

Date de publication:
2021
Historique:
entrez: 5 11 2021
pubmed: 6 11 2021
medline: 9 11 2021
Statut: epublish

Résumé

The global prevalence of chronic obstructive pulmonary disease (COPD) has increased markedly in recent decades. Given the scarcity of resources available to address global health challenges and respiratory medicine being relatively under-invested in, it is important to define research priorities for COPD globally. In this paper, we aim to identify a ranked set of COPD research priorities that need to be addressed in the next 10 years to substantially reduce the global impact of COPD. We adapted the Child Health and Nutrition Research Initiative (CHNRI) methodology to identify global COPD research priorities. 62 experts contributed 230 research ideas, which were scored by 34 researchers according to six pre-defined criteria: answerability, effectiveness, feasibility, deliverability, burden reduction, and equity. The top-ranked research priority was the need for new effective strategies to support smoking cessation. Of the top 20 overall research priorities, six were focused on feasible and cost-effective pulmonary rehabilitation delivery and access, particularly in primary/community care and low-resource settings. Three of the top 10 overall priorities called for research on improved screening and accurate diagnostic methods for COPD in low-resource primary care settings. Further ideas that drew support involved a better understanding of risk factors for COPD, development of effective training programmes for health workers and physicians in low resource settings, and evaluation of novel interventions to encourage physical activity. The experts agreed that the most pressing feasible research questions to address in the next decade for COPD reduction were on prevention, diagnosis and rehabilitation of COPD, especially in low resource settings. The largest gains should be expected in low- and middle-income countries (LMIC) settings, as the large majority of COPD deaths occur in those settings. Research priorities identified by this systematic international process should inform and motivate policymakers, funders, and researchers to support and conduct research to reduce the global burden of COPD.

Sections du résumé

BACKGROUND BACKGROUND
The global prevalence of chronic obstructive pulmonary disease (COPD) has increased markedly in recent decades. Given the scarcity of resources available to address global health challenges and respiratory medicine being relatively under-invested in, it is important to define research priorities for COPD globally. In this paper, we aim to identify a ranked set of COPD research priorities that need to be addressed in the next 10 years to substantially reduce the global impact of COPD.
METHODS METHODS
We adapted the Child Health and Nutrition Research Initiative (CHNRI) methodology to identify global COPD research priorities.
RESULTS RESULTS
62 experts contributed 230 research ideas, which were scored by 34 researchers according to six pre-defined criteria: answerability, effectiveness, feasibility, deliverability, burden reduction, and equity. The top-ranked research priority was the need for new effective strategies to support smoking cessation. Of the top 20 overall research priorities, six were focused on feasible and cost-effective pulmonary rehabilitation delivery and access, particularly in primary/community care and low-resource settings. Three of the top 10 overall priorities called for research on improved screening and accurate diagnostic methods for COPD in low-resource primary care settings. Further ideas that drew support involved a better understanding of risk factors for COPD, development of effective training programmes for health workers and physicians in low resource settings, and evaluation of novel interventions to encourage physical activity.
CONCLUSIONS CONCLUSIONS
The experts agreed that the most pressing feasible research questions to address in the next decade for COPD reduction were on prevention, diagnosis and rehabilitation of COPD, especially in low resource settings. The largest gains should be expected in low- and middle-income countries (LMIC) settings, as the large majority of COPD deaths occur in those settings. Research priorities identified by this systematic international process should inform and motivate policymakers, funders, and researchers to support and conduct research to reduce the global burden of COPD.

Identifiants

pubmed: 34737870
doi: 10.7189/jogh.11.15003
pii: jogh-11-15003
pmc: PMC8542376
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15003

Subventions

Organisme : Medical Research Council
ID : G1001372
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N02995X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S019669/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 by the Journal of Global Health. All rights reserved.

Déclaration de conflit d'intérêts

Competing interests: The authors completed the ICMJE Unified Competing Interest form (available upon request from the corresponding author), and declare no conflicts of interest. Igor Rudan and Harry Campbell are the Co-Editor in Chief of the Journal of Global Health. To ensure that any possible conflict of interest relevant to the journal has been addressed, this article was reviewed according to best practice guidelines of international editorial organisations.

Références

Lancet. 2017 May 13;389(10082):1931-1940
pubmed: 28513453
Lancet. 2012 Dec 15;380(9859):2163-96
pubmed: 23245607
Nature. 2011 Jul 06;475(7354):27-30
pubmed: 21734685
J Glob Health. 2015 Dec;5(2):020415
pubmed: 26755942
Lancet. 2012 Apr 7;379(9823):1341-51
pubmed: 22314182
Chest. 2021 Feb;159(2):575-584
pubmed: 33038390
Respir Res. 2019 Dec 21;20(1):291
pubmed: 31864411
COPD. 2019 Dec;16(5-6):311-320
pubmed: 31576763
Lancet Infect Dis. 2007 Jan;7(1):56-61
pubmed: 17182344
BMJ Open. 2012 Nov 19;2(6):
pubmed: 23166130
Prim Care Respir J. 2012 Mar;21(1):19-27
pubmed: 22273628
Am J Respir Crit Care Med. 2013 Feb 1;187(3):320-6
pubmed: 23155144
Lancet Respir Med. 2015 Feb;3(2):159-170
pubmed: 25680912
Science. 2003 Oct 17;302(5644):398-9
pubmed: 14563993
J Glob Health. 2016 Jun;6(1):010502
pubmed: 27350873
Lancet Respir Med. 2020 Jun;8(6):585-596
pubmed: 32526187
Croat Med J. 2008 Dec;49(6):720-33
pubmed: 19090596
J Glob Health. 2016 Jun;6(1):010301
pubmed: 26401269
Eur Respir Rev. 2015 Jun;24(136):159-72
pubmed: 26028628
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Respirology. 2017 Apr;22(3):575-601
pubmed: 28150362
Nature. 2007 Nov 22;450(7169):494-6
pubmed: 18033288
J Glob Health. 2016 Jun;6(1):010508
pubmed: 26401272
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
J Glob Health. 2016 Jun;6(1):010503
pubmed: 27350874
COPD. 2021 Apr;18(2):133-146
pubmed: 33779454
Eur Respir J. 2019 Sep 5;54(3):
pubmed: 31488589
JMIR Res Protoc. 2015 Aug 12;4(3):e103
pubmed: 26268741
Public Health. 2012 Mar;126(3):237-240
pubmed: 22325672
Thorax. 2007 Jan;62(1):5-7
pubmed: 17189530
Health Expect. 2005 Sep;8(3):253-63
pubmed: 16098155
J Glob Health. 2016 Jun;6(1):010303
pubmed: 27303649
Eur Respir J. 2020 Aug 13;56(2):
pubmed: 32817205
J Glob Health. 2016 Jun;6(1):010501
pubmed: 27418959
BMC Med. 2015 Jul 02;13:157
pubmed: 26137986
J Glob Health. 2017 Jun;7(1):011004
pubmed: 28685049
Am J Respir Crit Care Med. 2018 Feb 1;197(3):289-299
pubmed: 29388824
Bull World Health Organ. 2009 Jun;87(6):438-46
pubmed: 19565122
Lancet. 2009 Nov 28;374(9704):1857-62
pubmed: 19944866
J Glob Health. 2019 Jun;9(1):010422
pubmed: 30842883
Thorax. 2019 Aug;74(8):727-729
pubmed: 31285362
Lancet Respir Med. 2020 Aug;8(8):e67-e68
pubmed: 32763207
J Glob Health. 2016 Jun;6(1):010302
pubmed: 27350870
Lancet Neurol. 2016 Nov;15(12):1285-1294
pubmed: 27751558
Int J Chron Obstruct Pulmon Dis. 2012;7:457-94
pubmed: 22927753

Auteurs

Davies Adeloye (D)

Usher Institute, University of Edinburgh, Edinburgh, UK.

Dhiraj Agarwal (D)

Vadu Rural Health Program, KEM Hospital Research Centre, Pune, India.

Peter J Barnes (PJ)

Imperial College London, UK.

Marcel Bonay (M)

University of Versailles, Versailles, France.

Job F van Boven (JF)

University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), Department of Clinical Pharmacy & Pharmacology, Groningen, the Netherlands.

Jamie Bryant (J)

University of Newcastle, Newcastle, New South Wales, Australia.

Gaetano Caramori (G)

University of Messina, Messina, Italy.

David Dockrell (D)

Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.

Anthony D'Urzo (A)

University of Toronto, Toronto, Ontario, Canada.

Magnus Ekström (M)

Lund University, Lund, Sweden.

Gregory Erhabor (G)

Obafemi Awolowo University, Ile-Ife, Nigeria.

Cristóbal Esteban (C)

Galdakao-Usansolo Hospital, Galdakao, Bizkaia, Spain.

Catherine M Greene (CM)

Royal College of Surgeons in Ireland, Dublin, Ireland.

John Hurst (J)

UCL Respiratory, University College London, UK.

Sanjay Juvekar (S)

Vadu Rural Health Program, KEM Hospital Research Centre, Pune, India.

Ee Ming Khoo (EM)

Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Fanny W Ko (FW)

The Chinese University of Hong Kong, Hong Kong.

Brian Lipworth (B)

Scottish Centre for Respiratory Research, University of Dundee, Dundee, UK.

Jose L López-Campos (JL)

Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS); Hospital Universitario Virgen del Rocio - Universidad de Sevilla - CIBERES, Spain.

Matthew Maddocks (M)

Kings College London, UK.

David M Mannino (DM)

University of Kentucky, Lexington, Kentucky, USA.

Fernando J Martinez (FJ)

Weill Cornell Medicine, New York City, New York, USA.

Miguel A Martinez-Garcia (MA)

Hospital Universitario y Politécnico de La Fe, Valencia, Spain.

Renae J McNamara (RJ)

The University of Sydney, New South Wales, Australia.

Marc Miravitlles (M)

Pneumology Department, University Hospital Vall d'Hebron and Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.

Hilary Pinnock (H)

Usher Institute, University of Edinburgh, Edinburgh, UK.

Alison Pooler (A)

Keele University, Keele, UK.

Jennifer K Quint (JK)

Imperial College London, UK.

Peter Schwarz (P)

Bone-metabolic Research Unit, Copenhagen University Hospital Rigshospitalet, Denmark.

George M Slavich (GM)

Cousins Center for Psychoneuroimmunology and Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California, USA.

Peige Song (P)

School of Public Health, Zhejiang University School of Medicine, Hangzhou, China.

Andrew Tai (A)

Women's and Children's Hospital, Adelaide, South Australia, Australia.

Henrik Watz (H)

Pulmonary Research Institute at Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), German Centre for Lung Research (DZL), Germany.

Jadwiga A Wedzicha (JA)

Imperial College London, UK.

Michelle C Williams (MC)

Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.

Harry Campbell (H)

Usher Institute, University of Edinburgh, Edinburgh, UK.

Aziz Sheikh (A)

Usher Institute, University of Edinburgh, Edinburgh, UK.

Igor Rudan (I)

Usher Institute, University of Edinburgh, Edinburgh, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH